Intelligence Feed event · Macro · 2026-09-05

    Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint

    Question

    Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint

    Direct answer

    Novartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-05
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint”, revision 1, evidence through 2026-09-05. https://marketontology.com/market-events/2026-09-05/novartis-phase-3-pelacarsen-trial-fails-primary-cardiovascular-endpoint-e3b904

    MACRO
    Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
    Novartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment.
    NVSRPRXIONS
    Impact
    78
    SEP 5
    SIG
    90%
    NVSRPRXIONS
    Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
    Novartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment.
    → Negative clinical trial results eliminate future commercial royalty cash flows for IONS and compress RPRX valuation, while removing a pipeline growth driver for NVS.
    Impact
    Novartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment.
    Affected
    NVSRPRXIONS
    Transmission
    Negative clinical trial results eliminate future commercial royalty cash flows for IONS and compress RPRX valuation, while removing a pipeline growth driver for NVS.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    NVScardiovascular pipeline revenue write-downDown1-5dPhase 3 HORIZON trial for pelacarsen failed primary endpoint
    RPRXroyalty income curtailment mitigated by principal recoupment termsMixed1-5dRoyalty Pharma expects to recoup its $500 million investment despite trial miss
    IONSmilestone and downstream royalty cash flow lossDown1-5dIonis partnered asset failed pivotal Phase 3 endpoint

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSDownagreed58.09 2026-09-04-2.38%-11.45%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month